Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
154.06
-1.86 (-1.19%)
At close: Aug 28, 2026, 4:00 PM EDT
154.94
+0.88 (0.57%)
After-hours: Aug 28, 2026, 7:45 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $211.57. The average 1-year stock price forecast is 37.33% higher than the current stock price, while the lowest is $165 (+7.10%) and the highest is $249 (+61.63%).
Price Target: $211.57 (+37.33%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 19 | 20 | 21 | 19 | 19 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 27 | 28 | 29 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $182 | Hold | Maintains | $182 | +18.14% | Aug 25, 2026 |
| BMO Capital | BMO Capital | Hold Maintains $190 | Hold | Maintains | $190 | +23.33% | Aug 18, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $210 → $215 | Buy | Maintains | $210 → $215 | +39.56% | Aug 17, 2026 |
| Bernstein | Bernstein | Buy Maintains $221 → $218 | Buy | Maintains | $221 → $218 | +41.50% | Aug 13, 2026 |
| Deutsche Bank | Deutsche Bank | Hold Reiterates $190 → $165 | Hold | Reiterates | $190 → $165 | +7.10% | Aug 13, 2026 |
Financial Forecast
Revenue This Year
3.90B
from 2.86B
Increased by 36.39%
Revenue Next Year
4.55B
from 3.90B
Increased by 16.65%
EPS This Year
10.19
from 6.39
Increased by 59.45%
EPS Next Year
11.95
from 10.19
Increased by 17.32%
EPS and Forward PE are based on non-GAAP adjusted numbers.